A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment [Un trial randomizzato, di fase 2b, in aperto, sulla somministrazione di JX-594 (Virus vaccinico per GM-CSF e TK disattivato) piu' terapia di supporto ottimale vs. Terapia di supporto ottimale in pazienti affetti da carcinoma epatocellulare avanzato in cui il trattamento con sorafenib e' fallito]
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Pexastimogene devacirepvec (Primary) ; Pexastimogene devacirepvec (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms TRAVERSE
- Sponsors Jennerex
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 12 Sep 2013 A decision on the further development of Pexa-Vec in liver cancer will be announced in the fourth quarter of 2013, according to a Transgene media release.